Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer
- 335 Downloads
T cell infiltration of colorectal cancer is associated with improved clinical outcome, underlining the importance of the immune system in cancer control; however, immune checkpoints, including the inhibitory T cell molecules CTLA-4 and PD-1 that temper the native immune response, mitigating autoimmunity, are coopted by tumors to facilitate escape from immune surveillance. Blockade of CTLA-4 and PD-1 and its ligand PD-L1, expressed by many tumors, have shown impressive activity in melanoma, renal cell carcinoma, and lung cancer. Immune checkpoint inhibition has been less well studied in colorectal cancer, but preclinical and clinical investigations are in progress.
KeywordsColorectal cancer Immune checkpoint CTLA-4 PD-1 PD-L1 mCRC Immunomodulation Vaccine Colon cancer Ipilimumab Tremelimumab Nivolumab Lambrolizumab
Compliance with Ethics Guidelines
Conflict of Interest
Sandip P. Patel declares that he has no conflict of interest. Takuya Osada declares that he has no conflict of interest. Koya Osada declares that he has no conflict of interest. Herbert Hurwitz has received compensation for service as a consultant and is supported by grants from Roche, Genentech, Bristol-Myers Squibb, Sanofi-Aventis, Amgen, Regeneron, Novartis, TRACON, and Threshold Pharmaceuticals. H. Kim Lyerly declares that he has no conflict of interest. Michael A. Morse is supported be a grant from Bristol-Myers Squibb, and has received payment for lectures including service on speakers bureaus from Genentech.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Sandler A, Gray R, Ph D, et al.. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. 2006; 2542-2550Google Scholar
- 11.Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (Anti–PD-1) in Melanoma. N Engl J Med 0:nullGoogle Scholar
- 12.Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 0:nullGoogle Scholar
- 22.Francisco LM, Salinas VH, Brown KE, et al.: PD-L1 regulates the development , maintenance , and function of induced regulatory T cells. 206:3015–3029, 2009Google Scholar
- 37.• Pagès F, Kirilovsky A, Mlecnik B, et al. In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer. J Clin Oncol. 2009;27:5944–51. Development of prognostic immunoscore assessing effector and memory T cells within colorectal tumor specimens which are associated with improved prognosis.PubMedCrossRefGoogle Scholar
- 44.M. Grimm MG, M. Koenigshausen, C. Stein, J. Lutz, S. Krol, A. Thiede, U. Heemann and A. Waaga-Gasser: Abstract: Clinical significance and therapeutic potential of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human colorectal cancer. J Clin Oncol 26;:suppl 15005 (ASCO Meeting Abstracts), 2008Google Scholar
- 54.Simon Pernot MT, Marcheteau E, Voron T, Colussi O, Tartour E, Taïeb J. Impact of antiangiogenic treatments on exhausted PD-1+ T lymphocytes in colorectal cancer. J Clin Oncol, 2013Google Scholar
- 60.NCT01769222: Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer (Phase 1/2).Google Scholar
- 62.•• Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20. Excellent overview of the novel immune response criteria and definitions of progression related to all immunotherapeutics.PubMedCrossRefGoogle Scholar